

CITATION REPORT

List of articles citing

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy Associated Adverse Events

DOI: 10.1016/j.eursup.2008.08.001

European Urology Supplements, 2008, 7, 667-674.

Source: <https://exaly.com/paper-pdf/44137855/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
81	[Intravesical therapy in non-muscle-invasive bladder cancer: indications and practical considerations]. <i>Der Urologe</i> , 2009 , 48, 1263-4, 1266-8, 1270-2		
80	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, i-xii	2.6	
79	Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guérin-induced toxicity?. <i>BJU International</i> , 2009 , 104, 633-9	5.6	20
78	The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. <i>European Urology</i> , 2010 , 57, 410-29	10.2	125
77	Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer. <i>European Urology Supplements</i> , 2010 , 9, 715-734	0.9	19
76	Perioperative management of nonmuscle-invasive bladder cancer. <i>Current Opinion in Urology</i> , 2011 , 21, 403-8	2.8	1
75	Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. <i>BJU International</i> , 2011 , 108, 1210-4	5.6	7
74	Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. <i>International Journal of Urology</i> , 2011 , 18, 113-20	2.3	59
73	EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. <i>European Urology</i> , 2011 , 59, 997-1008	10.2	557
72	Re: Amit R. Patel, Edmund S. Sabanegh, J. Stephen Jones, et al. Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. <i>Eur Urol</i> 2010;58:934-7. <i>European Urology</i> , 2011 , 60, e7	10.2	
71	Added value of use of a purified protein derivative-based enzyme-linked immunosorbent spot assay for patients with Mycobacterium bovis BCG infection after intravesical BCG instillations. <i>Vaccine Journal</i> , 2012 , 19, 974-7		1
70	Antitumor effects of cis-urocanic acid on experimental urothelial cell carcinoma of the bladder. <i>Journal of Urology</i> , 2012 , 187, 1445-9	2.5	11
69	Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2012 , 187, 1195-9	2.5	28
68	[Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer]. <i>Progres En Urologie</i> , 2012 , 22, 920-31	0.9	8
67	Comment to «Acute Arthritis Secondary to Intravesical Bacillus Calmette-Guérin for Bladder Cancer» <i>Actas Urológicas Españolas (English Edition)</i> , 2012 , 36, 467-468	0.1	
66	[EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. <i>Actas Urológicas Españolas</i> , 2012 , 36, 389-402	0.7	49
65	[Comment to «acute arthritis secondary to intravesical bacillus Calmette-Guérin for bladder cancer»]. <i>Actas Urológicas Españolas</i> , 2012 , 36, 467-8	0.7	1

64	[Diagnosis and management of adverse events occurring during BCG therapy for non-muscle invasive bladder cancer (NMIBC): review of the Cancer Committee of the French Association of Urology]. <i>Progres En Urologie</i> , 2012 , 22, 989-98	0.9	7
63	EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. <i>Actas Urológicas Españolas (English Edition)</i> , 2012 , 36, 389-402	0.1	3
62	EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. <i>European Urology</i> , 2013 , 64, 639-53	10.2	906
61	Current intravesical therapy for non-muscle invasive bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1371-85	5.4	22
60	Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). <i>BJU International</i> , 2013 , 112, 742-50	5.6	61
59	Factors related to side effects of intravesical bacillus Calmette-Guérin: dose, maintenance treatment, and physicians?. <i>European Urology</i> , 2014 , 65, 77-8	10.2	1
58	Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. <i>European Urology</i> , 2014 , 65, 69-76	10.2	170
57	Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study. <i>BMC Urology</i> , 2014 , 14, 64	2.2	18
56	Non-muscle invasive bladder cancer and bacillus Calmette-Guerin treatment: a review of the literature. <i>International Journal of Urological Nursing</i> , 2015 , 9, 57-68	0.8	
55	Bacillus Calmette-Guérin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: A case report and literature review. <i>Molecular and Clinical Oncology</i> , 2015 , 3, 249-251	1.6	6
54	BCG treatment for bladder cancer, from past to present use. <i>International Journal of Urological Nursing</i> , 2015 , 9, 177-186	0.8	2
53	Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients. <i>Infectious Diseases</i> , 2015 , 47, 725-31	3.1	15
52	Intravesical therapy for bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 889-901	4	21
51	Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked!. <i>Infectious Diseases</i> , 2015 , 47, 732-3	3.1	1
50	Mycobacterium bovis and Other Uncommon Members of the Mycobacterium tuberculosis Complex. <i>Microbiology Spectrum</i> , 2016 , 4,	8.9	5
49	Case Presentation: Mycotic Aortic Aneurysm and Psoas Abscess as a Complication of Bacillus Calmette-Guérin Instillations. <i>European Urology Focus</i> , 2016 , 2, 351-353	5.1	0
48	Complications dans les suites d'une BCG thérapie intravésicale: épidémiologie, description clinique et prise en charge. <i>Journal Des Anti-infectieux</i> , 2016 , 18, 106-116		
47	Anti-tumor effect of Radix Paeoniae Rubra extract on mice bladder tumors using intravesical therapy. <i>Oncology Letters</i> , 2016 , 12, 904-910	2.6	26

46	[Persistent fever for more than 10 days in a urological patient]. <i>Der Urologe</i> , 2016 , 55, 1218-20		
45	Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy. <i>Actas Urológicas Españolas (English Edition)</i> , 2016 , 40, 370-377	0.1	
44	Spinal tuberculosis with severe neurological symptoms as a complication of intravesical BCG therapy for carcinoma of the bladder. <i>Neurologia I Neurochirurgia Polska</i> , 2016 , 50, 131-8	1	10
43	Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy. <i>Actas Urológicas Españolas</i> , 2016 , 40, 370-7	0.7	10
42	Bladder Contracture - A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy. <i>Urology Case Reports</i> , 2016 , 4, 22-4	0.5	2
41	EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>European Urology</i> , 2017 , 71, 447-461	10.2	1199
40	Imaging of Infections of the Urinary and Male Reproductive Tracts. <i>Seminars in Roentgenology</i> , 2017 , 52, 83-89	0.8	2
39	[BCGitis: An unusual complication after intravesical immunotherapy]. <i>Therapie</i> , 2017 , 72, 509-511	3.8	0
38	Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1379-1387	2.5	4
37	Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer. <i>IDCases</i> , 2017 , 10, 75-78		2
36	Intravesical Bacillus Calmette-Guérin Cystitis. <i>Current Bladder Dysfunction Reports</i> , 2017 , 12, 207-211	0.4	
35	[Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. <i>Pneumologie</i> , 2017 , 71, 325-397	0.5	44
34	Two cases of granulomatous hepatitis due to disseminated bacillus Calmette-Guérin (BCG) disease. <i>Acta Hepatologica Japonica</i> , 2017 , 58, 406-414	0.3	1
33	Mycobacterium bovis and Other Uncommon Members of the Mycobacterium tuberculosis Complex. 2017 , 753-765		
32	Managing Toxicity of Intravesical Therapy. <i>European Urology Focus</i> , 2018 , 4, 464-467	5.1	4
31	A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer. <i>International Journal of Infectious Diseases</i> , 2018 , 72, 63-68	10.5	8
30	Disseminated Mycobacterium bovis infection post-kidney transplant following remote intravesical BCG therapy for bladder cancer. <i>Transplant Infectious Disease</i> , 2018 , 20, e12931	2.7	12
29	Ibuprofen Decreases Spontaneous Activity and Enhances Nerve-Evoked Contractions to Minimize Mitomycin C-Induced Bladder Dysfunction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 366, 282-290	4.7	7

28	Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018 , 23, 135-147	3.7	7
27	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. <i>European Urology</i> , 2019 , 76, 639-657	10.2	531
26	The Inflammatory Contracted Bladder. <i>Current Bladder Dysfunction Reports</i> , 2019 , 14, 67-74	0.4	2
25	Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer. <i>Journal of Oncology</i> , 2019 , 2019, 6230409	4.5	22
24	Severe Infectious Complications of Intravesical Bacillus Calmette-Guérin: A Case Series of 10 Patients. <i>Urology</i> , 2020 , 137, 79-83	1.6	5
23	Withdrawing from treatment for Bladder cancer: Patient experiences of BCG installations. <i>International Journal of Urological Nursing</i> , 2020 , 14, 106-114	0.8	0
22	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 774-782	2.8	7
21	Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2020 , 19, 100149	2.1	5
20	Cold Atmospheric Plasma, a Novel Approach against Bladder Cancer, with Higher Sensitivity for the High-Grade Cell Line. <i>Biology</i> , 2021 , 10,	4.9	7
19	Supportive Care Needs of Patients on Surveillance and Treatment for Non-Muscle-Invasive Bladder Cancer. <i>Seminars in Oncology Nursing</i> , 2021 , 37, 151105	3.7	1
18	Approaches to Non-Muscle-Invasive Bladder Cancer. <i>Current Oncology Reports</i> , 2021 , 23, 105	6.3	3
17	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). <i>European Urology</i> , 2021 ,	10.2	51
16	Management of NMIBC during BCG shortage and COVID-19. <i>Trends in Urology & Men's Health</i> , 2021 , 12, 7-11	0.3	0
15	Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 1756287221995683	3.2	0
14	Mycobacterium bovis and Other Uncommon Members of the Mycobacterium tuberculosis Complex. 2011 , 607-617		2
13	Intravesical Bacillus Calmette-Guérin and its complications: 12 years of learning experience in a single local institution. <i>Singapore Medical Journal</i> , 2020 ,	1.9	0
12	Methylation status as a predictor of intravesical Bacillus Calmette-Guérin (BCG) immunotherapy response of high grade non-muscle invasive bladder tumor. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x00301; Olomouc, Czechoslovakia</i> , 2017 , 161, 210-216	1.7	11
11	Grundlagen der systemischen Therapie. 2009 , 123-167		

10	Vaccines. <i>Side Effects of Drugs Annual</i> , 2011 , 33, 653-668	0.2
9	Bladder Cancer. 2012 , 325-354	
8	Intravesical Therapy for Bladder Cancer. 2015 , 541-562	
7	BCG - history, method principle, indication, effectivity, dosage. <i>Urologie Pro Praxi</i> , 2019 , 20, 157-160	0.1
6	Adaptation of a side-effect questionnaire for identifying symptoms caused by bacillus Calmette-Guerin intravesical therapy. <i>International Journal of Urological Nursing</i> ,	0.8
5	Immune-modulating Effects of Mycobacteria.	
4	Role of oral pentosan polysulfate in Bacillus Calmette-Guérin therapy in patients with non-muscle-invasive bladder cancer. 2022 , 63, 539	0
3	Tuberkulose im Erwachsenenalter. 2022 , 76, 727-819	1
2	Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature. 2023 , 31, 100360	0
1	Indications and Use of Bowel in Female Lower Urinary Tract Reconstruction: Overview. 2023 , 1-30	0